THERAPEUTIC CLASS

Inhibition of oxidative phosphorylation suppresses the development of osimertinib resistance in a preclinical model of EGFR-driven lung adenocarcinoma

---

Metabolic plasticity is an emerging hallmark of cancer, and increased glycolysis is often observed in transformed cells. Small molecule inhibitors that target driver oncogenes can potentially inhibit the glycolytic pathway. Osimertinib (AZD9291) is a novel EGFR tyrosine kinase inhibitor (TKI) that is potent and selective for sensitising (EGFRm) and T790M resistance mutations.

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

LITERATURE

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Oncology

Specific Detail Info

Oncotarget, 2016, Vol. 7, (No. 52), pp: 86313-86325

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment